Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-02-16 00:00:00 ET · period of report 2022-02-14 · accession 0001209191-22-010175 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-16 | 2022-02-14 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $232.02 | -2,444 | 57.4K | -4% | -$567.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-14 | S | D | 2,444 | $232.02 | 57,438 | D | — | — | (F3) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F2) Open market sales reported on this line occurred at a weighted average price of $232.02 (range $231.82 to $232.60). |